C

    Castle Biosciences Inc (CSTL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $33.03
    -0.47 (-1.40%)

    Market Cap: $1.02B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(23/29)
    Avg Surprise
    +54.87%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.45 - $-0.25
    9 analysts
    EPS Revisions
    2
    0
    7d
    1
    7
    30d
    EPS Estimate Drift
    90d ago$-0.19+46.5%
    60d ago$-0.29+18.3%
    30d ago$-0.30+17.1%
    7d ago$-0.30+15.8%
    Current$-0.36
    Revenue Consensus
    $92M
    Range$90M - $93M
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.17 - $0.19
    9 analysts
    Revenue Consensus
    $115M
    Range$113M - $117M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.36---
    Jun 26
    		$-0.07N/A+84.09%Beat-146.7%
    Mar 26
    		$-0.49$-0.49+0.00%Beat+45.6%
    Dec 25
    		$-0.08N/A+65.22%Beat-125.0%
    Sep 25
    		$-0.02N/A+96.08%Beat-125.0%
    Jun 25
    		$0.15N/A+130.00%Beat-51.6%
    Mar 25
    		$-0.90$-0.07-1185.71%Miss-900.0%
    Dec 24
    		$0.32$0.04+700.00%Beat+420.0%
    Sep 24
    		$0.08$0.01+700.00%Beat+130.8%
    Jun 24
    		$0.31$-0.24+229.17%Beat+144.3%
    Mar 24
    		$-0.09N/A+70.97%Beat+91.8%
    Dec 23
    		$-0.10N/A+81.48%Beat+87.2%
    Sep 23
    		$-0.26N/A+64.38%Beat+66.2%
    Jun 23
    		$-0.70$-0.91+23.08%Beat-1066.7%
    Mar 23
    		$-1.10$-0.89-23.60%Miss-13.4%
    Dec 22
    		$-0.78$-0.84+7.14%Beat-212.0%
    Sep 22
    		$-0.77$-0.97+20.62%Beat-63.8%
    Jun 22
    		$-0.06N/A+92.50%Beat+82.9%
    Mar 22
    		$-0.97$-0.74-31.08%Miss-470.6%
    Dec 21
    		$-0.25$-0.47+46.81%Beat-47.1%
    Sep 21
    		$-0.47$-0.37-27.03%Miss-104.3%
    Jun 21
    		$-0.35$-0.39+10.26%Beat-337.5%
    Mar 21
    		$-0.17$-0.18+5.56%Beat-666.7%
    Dec 20
    		$-0.17$-0.12-41.67%Miss-254.5%
    Sep 20
    		$-0.23$-0.15-53.33%Miss-1250.0%
    Jun 20
    		$-0.08N/A+81.82%Beat+92.4%
    Mar 20
    		$0.03$-0.05+160.00%Beat+102.5%
    Dec 19
    		$0.11$-0.20+155.00%Beat-
    Sep 19
    		$0.02N/A+106.67%Beat-
    Jun 19
    		$-1.05$-1.36+22.79%Beat-
    Mar 19
    		$-1.22$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-50.05EV/EBITDA42.95x
    Price/FCF-2053.33xFCF Yield-0.05%
    Profitability
    Profit Margin-5.43%Operating Margin-2.96%
    ROE-4.20%ROIC1.81%
    Financial Health
    Debt/Equity0.02xInterest Coverage15.03x
    Current Ratio6.04xQuick Ratio5.85x
    Trading Statistics
    Beta0.97Avg Volume437.18K
    52-Week High$44.2852-Week Low$17.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$33.18
    SMA 20$32.10
    SMA 50$27.42
    SMA 200$29.44
    EMA 10$33.07
    EMA 20$31.71
    EMA 50$28.59
    EMA 200$26.83

    MACD

    Line: 1.91Signal: 2.00Hist: -0.08

    ADX

    ADX: 41.5+DI: 26.0-DI: 15.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down8.0
    PSAR$30.58

    Bollinger Bands

    Upper Band$35.55
    Lower Band$28.66
    %B Position2146%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    60.1

    Momentum Oscillators

    Stoch %K75.3
    Stoch %D81.4
    Williams %R-33.5
    ROC (10d)10.3%
    Momentum3.08
    CCI (20d)42.4
    MFI (14d)39.6

    Volatility Measures

    ATR (14d)$1.65(5.0%)
    StdDev (20d)1.72
    Hist Vol58.3%(High)

    Volume Flow

    VWAP$32.91
    OBV18.0M
    AD Line2.9M
    CMF (20d)0.053

    Volume Metrics

    Avg Vol (20d)419.8K
    Vol Ratio0.6x
    VWMA (20d)$31.99

    Pivot Points

    R3$35.73
    R2$35.00
    R1$34.25
    Pivot Point$33.52
    S1$32.77
    S2$32.05
    S3$31.30

    Advanced Oscillators

    TSI31.68
    Ultimate Osc58.5
    KST267.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$103.55M$83.68M$87.01M$83.04M$86.19M$87.99M$86.31M$85.78M$87.00M$72.97M$66.12M$61.49M
    Cost of Revenue$23.70M$20.53M$18.32M$18.70M$17.63M$16.38M$16.18M$15.61M$14.52M$13.89M$12.42M$11.32M
    Gross Profit$79.85M$63.15M$68.69M$64.34M$68.56M$71.61M$70.13M$70.17M$72.48M$59.08M$53.70M$50.17M
    Operating Expenses$82.92M$81.55M$72.52M$71.14M$72.81M$99.53M$66.08M$65.09M$67.47M$64.55M$59.35M$59.81M
    R&D$14.54M$14.43M$13.52M$12.96M$12.79M$12.59M$11.77M$12.32M$14.14M$13.81M$12.99M$12.92M
    SG&A$66.12M$64.90M$56.73M$55.91M$58.06M$58.62M$49.97M$50.50M$51.09M$48.49M$44.09M$44.62M
    Operating Income$-3,070,000$-18,407,000$-3,827,000$-6,804,000$-4,251,000$-27,928,000$4.05M$5.08M$5.01M$-5,471,000$-5,658,000$-9,640,000
    Interest Income$1.73M$2.54M$801,000$6.39M$4.13M$3.10M$3.93M$3.40M$3.14M$3.00M$3.12M$2.77M
    Interest Expense$193,000$134,000$24,000$24,000$21,000$17,000$92,000$201,000$270,000$14,000$2,000$2,000
    Income Before Tax$-1,690,000$-14,413,000$-2,714,000$-386,000$-143,000$-26,271,000$7.88M$8.28M$7.89M$-2,489,000$-2,541,000$-6,873,000
    Income Tax Expense$370,000$109,000$-382,000$115,000$-4,666,000$-423,000$-1,705,000$6.01M$-1,034,000$45,000$39,000$32,000
    Net Income$-2,060,000$-14,522,000$-2,332,000$-501,000$4.52M$-25,848,000$9.59M$2.27M$8.92M$-2,534,000$-2,580,000$-6,905,000
    EBITDA$455,000$-13,349,000$-422,000$-3,845,000$-2,008,000$-1,024,000$8.21M$6.97M$6.64M$-3,830,000$-4,074,000$-8,035,000
    EBIT$-3,223,000$-16,824,000$-3,491,000$-6,756,000$-4,251,000$-29,353,000$4.05M$5.08M$5.01M$-5,471,000$-5,658,000$-9,640,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CSTL

    Government Contracts

    Gov Obligations (TTM)
    -$135000
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Castle Biosciences CCO Tobin W sells $51,190 in stock

    Juvenal Tobin W, Chief Commercial Officer at Castle Biosciences Inc., sold 1,730 shares of the company's common stock for a total of $51,190. This sale was conducted under a Rule 10b5-1 trading plan and occurred amidst a significant rally in the company's stock, which has seen a 64% return over the past year. Despite the sale, Castle Biosciences recently reported strong second-quarter results, beating analyst expectations and raising its full-year sales guidance, leading to a raised price target from BTIG.

    Investing.com•8/26/26•
    Neutral

    Castle Biosciences (NASDAQ: CSTL) CCO lines up sale of 22,500 shares

    Castle Biosciences' Chief Commercial Officer, Tobin Juvenal, has filed a Rule 144 notice for the potential sale of 22,500 shares of common stock, valued at $787,500, through Goldman Sachs & Co. LLC. These shares are related to equity compensation awards granted between 2022 and 2025 and are part of a pre-planned selling arrangement compliant with Rule 10b5-1(c). The filing notes 30,549,507 shares outstanding and also reports recent sales by Juvenal in August 2026.

    Stock Titan•8/25/26•
    Neutral

    Parkman Healthcare Partners LLC Invests $3.45 Million in Castle Biosciences, Inc. $CSTL

    Parkman Healthcare Partners LLC has purchased a new stake of 144,791 shares, valued at approximately $3.45 million, in Castle Biosciences, Inc. The investment firm now owns about 0.47% of the company. This comes as institutional investors collectively hold 92.6% of CSTL, while company insiders have recently sold shares worth $3.84 million.

    MarketBeat•8/25/26•
    Neutral

    Castle Biosciences officer plans $841K share sale | CSTL SEC Filing - Form 144

    An officer of Castle Biosciences (CSTL), Kristen M. Oelschlager, has filed a Rule 144 notice for a proposed sale of 24,602 shares of common stock, valued at $841,388.40. The shares are held by The Fritz Shorter Trust, with Oelschlager as a trustee, and J.P. Morgan Securities LLC will handle the sale. This filing indicates a neutral impact and sentiment according to Rhea-AI.

    Stock Titan•8/24/26•
    Neutral

    Castle Biosciences surges 67% after InvestingPro Fair Value call By Investing.com

    Castle Biosciences (NASDAQ:CSTL) saw a remarkable 67% return in three months after InvestingPro's Fair Value analysis identified it as significantly undervalued in May 2026. The stock surged from $18.63 to $34.20, exceeding the initial Fair Value projection of $28.20. This success highlights how systematic Fair Value analysis, which aggregates multiple valuation approaches, can identify mispriced opportunities and provide investors with comprehensive insights into a stock's intrinsic worth.

    Investing.com•8/23/26•
    Bullish

    Frequently Asked Questions About CSTL

    Does CSTL pay dividends?
    Castle Biosciences Inc (CSTL) does not currently pay a regular dividend.
    What is CSTL's market cap?
    Castle Biosciences Inc (CSTL) has a market capitalization of $1.02B with a current stock price of $33.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In